Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 10, 2011, Pages 688-694

  Ma, Zhihong ^a   Zhang, Jianping ^a   Ji, Ensheng ^a   Cao, Gang ^a   Li, Guoming ^a   Chu, Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant; Fasudil; Hypercholesterolemia; Rats; Rho kinase

Indexed keywords

CATALASE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NITRIC OXIDE; RHO KINASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXPERIMENTAL RAT; HEART; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIVER CELL; LIVER WEIGHT; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANTIOXIDANTS; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIVER; MALE; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES;

EID: 80053168230     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05561.x     Document Type: Article

References (37)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 2002; 8: 1211-7.
2. Bocan TM. Animal models of atherosclerosis and interpretation of drug intervention studies. Curr. Pharm. Des. 1998; 4: 37-52.
3. Bulur H, Ozdemirler G, Oz B, Toker G, Ozturk M, Uysal M. High cholesterol diet supplemented with sunflower seed oil but not olive oil stimulates lipid peroxidation in plasma, liver, and aorta of rats. J. Nutr. Biochem. 1995; 6: 547-50.
4. Shi WB, Haberland ME, Jien ML, Shih DM, Lusis AJ. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation 2000; 102: 75-81.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989; 320: 915-24.
6. Wilcox JN, Subramanian RR, Sundell CL et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2479-88.
7. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000; 87: 840-4.
8. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005; 183: 1-16.
9. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62.
10. Ming XF, Viswambharan H, Barandier C et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 2002; 22: 8467-77.
11. Sawada N, Itoh H, Ueyama K et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000; 101: 2030-3.
12. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-4.
13. Takemoto M, Liao JK. Pletiotropic efects of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1712-9.
14. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: 1495-500.
15. Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: 243-50.
16. Deepa PR, Varalakshmi P. Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis. Clin. Chim. Acta 2004; 339: 105-15.
17. Rikitake Y, Kim HH, Huang ZH et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251-7.
18. Shah DI, Singh M. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can. J. Physiol. Pharmacol. 2006; 84: 835-45.
19. Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPARα-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 2003; 44: 2049-58.
20. Kikuchi Y, Yamada M, Imakiire T et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 2007; 192: 595-603.
21. Halliwell B. Mechanism involved in generation of free radicals. Pathol. Biol. 1996; 44: 6-13.
22. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am. Heart J. 1993; 125: 958-73.
23. Sheela CG, Angusti K. Antiperoxide effects of S-allyl cystein sulphoxide isolated from Allium sativum Linn and gugulipid in chlosterol diet fed rats. J. Exp. Biol. 1995; 33: 337-41.
24. Lee P, Prasad K. Effects of flaxseed oil on serum lipids and atherosclerosis in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. Therapeut. 2003; 8: 61-9.
25. Shiotani S, Shimada M, Suehiro T et al. Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats. Transplantation 2004; 78: 375-82.
26. Huang L, He Z, Guo LJ, Wang HX. Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of Rho-kinase. Cell. Mol. Neurobiol. 2008; 28: 757-68.
27. Higashi M, Shimokawa H, Hattori T et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 2003; 93: 767-75.
28. Gojo A, Utsunomiya K, Taniguchi K et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007; 568: 242-7.
29. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 285: 277-97.
30. Miller AA, De Silva TM, Judkins CP, Diep H, Drummond GR, Sobey CG. Augmented superoxide production by Nox2-containing NADPH oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 2010; 41: 784-9.
31. Pignatelli P, Carnevale R, Cangemi R et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 360-7.
32. Carnevale R, Pignatelli P, Di Santo S et al. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 2010; 213: 225-34.
33. Deepa PR, Varalakshmi P. Favourable modulation of the inflammatory changes in hypercholesterolemic atherogenesis by a low-molecular-weight heparin derivative. Int. J. Cardiol. 2006; 106: 338-47.
34. Deliconstantinos G, Villiotou V, Stavrides JC. Modulation of particulate nitric oxide synthase activity and peroxynitrite synthesis in cholesterol enriched endothelial cell membranes. Biochem. Pharmacol. 1995; 49: 1589-600.
35. Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1842-7.
36. Laufs U, Endres M, Stagliano N et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 2000; 106: 15-24.
37. Deepa PR, Varalakshmi P. Salubrious effect of low molecular weight heparin on atherogenic diet-induced cardiac, hepatic and renal lipid peroxidation and collapse of antioxidant defences. Mol. Cell. Biochem. 2003; 254: 111-6.